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We analyzed the modulation of serotonin on the bradycardia induced in vivo by vagal electrical stimulation in alloxan-induced
long-term diabetic rats. Bolus intravenous administration of serotonin had a dual eﬀect on the bradycardia induced either by
vagal stimulation or exogenous Ach, increasing it at low doses and decreasing it at high doses of 5-hydroxytryptamine (5-HT),
eﬀect reproduced by 5-carboxamidotryptamine maleate (5-CT), a 5-HT1/7 agonist. The enhancement of the bradycardia at low
doses of 5-CT was reproduced by 5-HT1A agonist 8-hydroxy-2-dipropylaminotetralin hydrobromide (8-OH-DPAT) and abolished
by WAY-100,635, 5-HT1A antagonist. Pretreatment with 5-HT1 antagonist methiothepin blocked the stimulatory and inhibitory
eﬀect of 5-CT, whereas pimozide, 5-HT7 antagonist, only abolished 5-CT inhibitory action. In conclusion, long-term diabetes
elicits changes in the subtype of the 5-HT receptor involved in modulation of vagally induced bradycardia. Activation of the 5-
HT1A receptors induces enhancement, whereas attenuation is due to 5-HT7 receptor activation. This 5-HT dual eﬀect occurs at
pre- and postjunctional levels.
1.Introduction
The role of 5-hydroxytryptamine (5-HT) in cholinergic neu-
rotransmission and parasympathetic cardiovascular eﬀects
has received considerable attention over many years. Central
5-HT1A, 5-HT3, and 5-HT7 receptors have a physiological
role in the regulation of cardiovascular reﬂexes, controlling
changes in parasympathetic (vagal) drive to the heart [1].
Recently, Ni et al. [2] revealed the existence of a local 5-
hydroxytryptaminergic system in peripheral arteries, but the
physiological role of 5-HT in the regulation of vascular tone
remains unclear. Some studies have proposed potent depo-
larizing actions, with an increase in vagal activity mediated
by activation of 5-HT3 and 5-HT2 [3], 5-HT4 [4], or 5-HT1A
receptors in diﬀerent animal species [5–9]. Other reports
have suggested an inhibitory serotonergic eﬀect on acetyl-
choline (Ach) release via activation of 5-HT1 receptors [10].
We have shown that, in pithed rats, the serotonergic
mechanisms involved in cardiac cholinergic neurotransmis-
sion are presynaptic and that they can dually inhibit or
facilitate acetylcholine release via activation of 5-HT2 or
5HT3 receptors, respectively [11]. We have also shown that
experimental diabetes elicits changes in the nature and 5-
HT receptor type/subtype involved in vagal bradycardia
stimulated by electrical means [12].
Diabetes mellitus (DM) is considered to be an important
public health problem owing to its increasing prevalence and
b e c a u s ei tc a u s e sa n de x a c e r b a t e sm a c r o -a n dm i c r o v a s c u l a r
complications. These are associated with severe debilitating
complications that include a diabetic autonomic neuropathy
characterized in part by impaired cardiac parasympathetic
responsiveness. Such parasympathetic dysfunction in the
diabetic heart may lead to an autonomic imbalance that may
predispose the heart to ventricular arrhythmias and sudden2 Experimental Diabetes Research
death [13]. Long-term diabetes reduces the body’s ability to
ﬁnely regulate heart rate (HR); this is attributed to profound
disturbances in autonomic function [14] which are probably
due to parasympathetic dysfunction [12, 15]. Several studies
conducted under diﬀerent conditions have supported the
theory that, during the development of diabetes, there
are impaired myocardial responses to muscarinic activation
by acetylcholine. These responses are related to hyper- or
hyposensitization and may include changes in expression of
muscarinic receptors [16–18]. Other studies have suggested
that diabetes induces changes in cholinergic transmission
[15, 19].
The aim of the present study was to analyze the possible
changes induced by experimental long-term diabetes to
5-HT on the in vivo cardiac response to activation of
parasympathetic nerves. This was achieved by examining the
serotonergic receptors involved in the cholinergic cardiac
responses to vagal electrical stimulation or by the admin-
istration of exogenous acetylcholine during experimental
alloxan-induced diabetes.
2.MaterialandMethods
The housing conditions of the rats and experimental pro-
cedures were in accordance with regulations set by the
European Union on the use of animal for scientiﬁc purposes
(86/609/EEC, Article 5, Appendix II) and enacted by Spanish
legislation on March 14, 1988 (R.D.223/1988).
2.1. Animal Preparation. Two hundred ﬁfty-ﬁve male Wistar
rats (250–350g) were used in the present study. Rats
were supplied and maintained by the Animalarium of the
Faculty of Pharmacy at the University of Salamanca (Spain;
PAE-SA001). Diabetes was induced by a single injection
of alloxan (150mg/kg, s.c.) dissolved in 0.9% NaCl. Rats
were maintained on tap water, and food was available ad
libitum for 8 weeks. A second group of animals were kept
as control normoglycaemic group for eight weeks. Body
weight, systolic blood pressure, heart rate, and blood glucose
levels were determined before and at 2, 7, 14, 21, 28,
35, 42, 49, and 56 days after alloxan administration. Only
rats with elevated blood glucose levels (>11mM) at all
time points were considered to be diabetic. Blood glucose
levels were determined by test strips (Accu-Chek). Systolic
blood pressure and heart rate were measured in awake rats
periodically using the tail-cuﬀ method with a photoelectric
sensor (NIPREM 546, Cibertec S.A., Madrid, Spain). Several
determinationsweremadeineachsessionforeachrat.Values
were considered to be valid if ﬁve consecutive measurements
were within 10mmHg.
Eight-week diabetic rats and four-week diabetic rats
were anaesthetized with sodium pentobarbital (60mg/kg,
i.p.). After cannulation of the trachea, rats were pithed
by inserting a stainless steel rod through the orbit and
foramen magnum [20]. They were then artiﬁcially respirated
with room air using a Harvard respiratory pump (1mL
air/100g, 50strokes/min; Harvard Apparatus, South Natick,
MA, USA). The right and left jugular veins were cannulated
for the infusion of agonists and antagonists, respectively.
Arterial blood pressure was monitored from the left
carotid artery cannula using a pressure transducer connected
to a PRS 206 ampliﬁer (Cibertec). Heart rate was measured
by analyses of blood pressure data with a CAR 306 cardiota-
chograph (Cibertec). Data on blood pressure and heart rate
were shown on a Letica Polygraph 4000 (Cibertec).
Both vagus nerves were isolated, ligated at the cervical
level, and cut rostrally to the ligature to prevent aﬀerent and
eﬀerent vagal reﬂexes. Electrical stimulation was applied as
square wave pulses from a Cibertec Stimulator CS-9 (supra-
maximal intensity: 15 ± 3V ;1m s e c ;3 ,6 ,a n d9H zf o r1 5sa t
5-minintervals)withaplatinumbipolarelectrodeconnected
to the caudal stump of the right cervical vagus nerve.
Beforeelectricalstimulation,ratsweretreatedwithhepa-
rin (1000UI/kg). Then, they were given D-tubocurarine
(2mg/kg, i.v.), to avoid electrically induced muscular twitch-
ing, and atenolol (1mg/kg, i.v.), to prevent sympathetic
eﬀects. Rats were kept warm (37.5 ± 0.5◦C) with a heating
lamp.
2.2. Experimental Protocols. After the hemodynamic status
of the rats had been stable for ≥10min, baseline values for
meanblood pressure(MBP)and heartrateweredetermined.
A platinum bipolar electrode was applied to the caudal
stump of the right cervical vagus nerve and electrical
stimulation applied as square wave pulses from a Cibertec
stimulator applying trains of 15s which consisted of pulses
of 1msec duration and supramaximal intensity (15 ± 3V)
at increasing frequencies (3, 6, and 9Hz). Thus, the control
stimulation response curve was completed in ∼15min.
At this point, rats were divided into seventh agonist or
antagonist treatment groups (n = 5 rats/group).
The ﬁrst group of experiments was conducted in nor-
moglycaemic (kept in parallel during eight weeks) and four-
weekdiabeticratstoconﬁrmpreviousdatafromourresearch
team [11, 12]. Each group was subdivided in two. The ﬁrst
subgroup received an i.v. bolus of saline solution (1mL/kg;
n = 5)asacontrolforthatgroupsofexperimentsor5-HT(5,
10,50,100,and200μg/kg,n = 5foreachdose).Fiveminutes
after the treatment, a new stimulation response curve was
obtained. In the second subgroup (n = 10), the eﬀects of
saline solution (1mL/kg; n = 5) or 5-HT (100μg/kg, n = 5)
on the bradycardia induced by exogenous acetylcholine (1, 5,
and 10μg/kg) were investigated. In this group, acetylcholine
was administered before (control curve) and 5min after
pretreatment with saline solution or 5-HT.
In the ﬁrst long-term alloxan-treated diabetic group
(n = 80), rats received an i.v. bolus of one of the following:
(i) saline solution (1mL/kg, n = 5, control group for
all the agonist treatments); (ii) 5-HT at 5, 10, 50, 100,
and 200μg/kg (n = 25); (iii) 5-carboxamidotryptamine
maleate (5-CT; selective 5-HT1/7 receptor agonist) at 5,
10, 50, 100, and 200μg/kg (n = 25); (iv) 150μg/kg of
α-methyl-5-hydroxytryptamine (selective 5-HT2 receptor
agonist n = 5); (v) 150μg/kg of 1-phenylbiguanide
(selective 5-HT3 receptor agonist; n = 5); (vi) 50μg/kg of 8-
hydroxydipropylaminotretalin hydrobromide (8-OH-DPAT;
selective 5-HT1A receptor agonist; n = 5); (vii) 50μg/kg of
CGS-12066B (agonist of the rodent 5-HT1B receptor; n = 5);Experimental Diabetes Research 3
Table 1: Values of body weight, systolic blood pressure, heart rate, and glycaemia in control and diabetic rats.
Body weight (g) Systolic blood pressure (mmHg) Heart rate (bpm) Glycaemia (mM) n
Control rats
Initial time 219 ± 9.0 118 ± 5.0 375 ± 10.0 5.6 ± 0.2 40
8 weeks after 424 ± 16.0 130 ± 4.0 392 ± 15.0 4.8 ± 0.1 40
Diabetic rats
Initial time 192 ± 10.0 124 ± 5.0 310 ± 6.0 5.6 ± 0.1 175
8 weeks after 309 ± 11.8∗ 157 ± 0.7∗ 365 ± 10.0 20.1 ± 0.7∗ 175
Results are means ± SEM for “n”r a t s .
∗Signiﬁcantly diﬀerent from the corresponding value in control rats, P<. 05.
(viii) 50μg/kg of L-694,247 (selective agonist for nonrodent
5-HT1B and 5-HT1D receptors; n = 5). Five minutes after the
corresponding administration, a new stimulation response
curve was obtained.
The second long-term alloxan-treated diabetic group
(n = 30) was run in parallel with the group described
above. The eﬀect of saline solution (1mL/kg), 100μg/kg
of methiothepin (n = 5), a nonselective 5-HT1 receptor
antagonist, or 100μg/kg of WAY-100,635 (n = 5), a selective
5-HT1A receptor antagonist, or 1mg/kg of GR55562 (n = 5),
a selective 5-HT1B receptor antagonist, or 1mg/kg of BRL-
15572 (n = 5), a selective 5-HT1D receptor antagonist, and
1mg/kg of pimozide (n = 5), a selective 5-HT7 receptor
antagonist, was observed.
The third long-term alloxan-treated diabetic group
(n = 25) was used to determine which receptor subtype
was involved in regulating the eﬀect of 5-HT on heart
rate. Methiothepin (100μg/kg), WAY-100,635 (100μg/kg),
GR55562 (1mg/kg), BRL-15572 (1mg/kg), or pimozide
(1mg/kg) were, respectively, administered 5min before 5-
CT (10, 100μg/kg, n = 10), 8-OH-DPAT (50μg/kg, n =
5), CGS-12066B (50μg/kg, n = 5), or L-694,247 (50μg/kg,
n = 5), respectively. Five minutes after each treatment, a new
stimulation response curve was obtained.
In the fourth group, rats received an i.v. bolus of
atropine (0.3 or 0.5mg/kg, n = 5 for each dose) before
electrical stimulation to conﬁrm that cholinergic responses
were induced by electrical stimulation.
In the ﬁnal group of long-term diabetic rats (n = 30),
the eﬀects of saline solution (1mL/kg; n = 5), 5-HT (10 and
100μg/kg, n = 5 for each dose), 5-CT (10 and 100μg/kg,
n = 5 for each dose), and 8-OH-DPAT (50μg/kg, n = 5)
were examined on the bradycardia induced by exogenous
acetylcholine (1, 5, and 10μg/kg), which was administered
before (control curve) and 5min after drug pretreatment.
2.3. Drugs Used. The anaesthetic (pentobarbital sodium)
was obtained from Sigma-Aldrich, (St. Louis, MO, USA).
Heparin sodium was from Roche (Madrid, Spain). Alloxan
and d-tubocurarine hydrochloride were purchased from
Sigma-Aldrich. 5-hydroxytryptamine creatinine sulphateco-
mplex (5-HT), methiothepin mesylate, 5-carboxamidotry-
ptamine maleate (5-CT), 7-triﬂuoromethyl-4-(4-methyl-1-
piperazinyl)pyrrolo[1,2-a-]-quinoxaline dimaleate (CGS-12
066B dimaleate), 2-[5-[3-(4-methylsulfonylamino)benzyl-1,
2,4-oxadiazol-5-yl]-1H-indol-3-yl]ethanamine (L-694,247),
α-methyl-5-hydroxytryptamine maleate (α-methyl-5-HT),
1-[1-[4,4-Bis(4-ﬂuorophenyl)butyl]-4-piperidinyl]-1,3-di-
hydro-2H-benzimidazol-2-one (pimozide), (S)-N-ter-butyl-
3-(4-(2-methoxyphenyl)-piperozin-1-yl)-2-phenylpropana-
mide dihydrochloride (WAY-100,635), 8-hydroxy-2-dipro-
pylaminotetralin hydrobromide (8-OH-DPAT), and 3-[4-
(4-chlorophenyl) piperazin-1-yl]-1,1-diphenyl-2-propanol
hydrochloride (BRL-12572) hydrochloride were purchased
from Tocris Cookson Limited (Ellisville, MO, USA).
Atropine sulphate was from Scharlau (Barcelona, Spain),
and atenolol was from Sigma-Aldrich.
All drugs used were dissolved in distilled water at the
time of experimentation, with the exception of BRL-15572
(dissolved in 20% propylene glycol) and pimozide (dissolved
in 0.01M HCl).
2.4. Statistical Analyses. Data are mean ± SEM of at least
ﬁve experiments (n = 5). Comparison of results between
experimental groups and their corresponding control group
were undertaken using ANOVA followed by the Newman-
Keuls multiple comparison test. Diﬀerences were considered
to be statistically signiﬁcant if P<. 05.
3. Results
3.1. Systemic Hemodynamic Variables. Alloxan-induced dia-
betes elicited a marked increase in serum glucose levels and
systolic blood pressure. Diabetic rats failed to increase their
body weight compared with control rats. Table 1 shows the
mean values of body weight, systolic blood pressure, heart
rate, and glycaemia before and 8 weeks after the induction
of diabetes for rats in the diabetic group and in the control
group.
Resting blood pressure and heart rate were 43.2 ±
2mmHg and 270 ± 4.9 beats per minute, respectively, in
eight-week diabetic anaesthetized pithed rats and 40.5 ±
1.5mmHg and 290 ± 5.0 beats per minute in anaesthetized
four-week diabetic rats. These values were not altered
signiﬁcantlybythei.v.administrationofasalinebolus,5-HT
receptor agonists (5-HT, 5-CT, 8-OH-DPAT, CGS-12066B,
L-694,247, α-methyl-5-HT, and 1-phenylbiguanide) or the
5-HT receptor antagonists (methiothepin, pimozide, BRL-
15572, GR55562, and WAY-100,635) (data not shown).4 Experimental Diabetes Research
3.2. Eﬀects of Physiological Saline or 5-HT on Vagally Induced
Bradycardiain Normoglycaemic and Four-Week Diabetic Rats.
Electrical stimulation of the right vagus nerve in normogly-
caemic and four-week diabetic rats resulted in frequency-
dependent bradycardia. In both groups the decrease in heart
rate remained stable after i.v. administration of a bolus of
saline solution (1mL/kg).
In normoglycaemic rats, the lowest doses of 5-HT (5,
10μg/kg, n = 10) did not modify the vagally induced brady-
cardia at the frequencies tested; the administration of 50 and
100μg/kg (n = 10) caused an attenuation of the bradycardia,
and the highest dose of 5-HT (200μg/kg, n = 5) resulted in
an increase of the vagally induced bradycardia (Figure 1(a)).
In four-week diabetic rats, the lowest doses of 5-HT (10
and 50μg/kg, n = 10) did not signiﬁcantly modify the
vagally induced bradycardia in the stimulation frequency
range tested (Figure 1(b)). However, high doses of 5-HT
(100 and 200μg/kg, n = 10) caused an increase in
the bradycardia, although this was only signiﬁcant at the
stimulation frequency of 3Hz (Figure 1(b)).
The stimulatory actions on vagal stimulation-induced
bradycardia in diabetic rats were also observed after admin-
istration of exogenous acetylcholine (data not shown).
3.3. Eﬀects of Physiological Saline or 5-HT on Vagally Induced
Bradycardia in Long-Term Diabetic Rats. Electrical stimu-
lation of the right vagus nerve in diabetic rats resulted in
frequency-dependent bradycardia. This electrically-induced
bradycardia, in the long-term diabetic rats, was less pro-
nounced than the bradycardia obtained under identical
conditions in four-week diabetic rats. These diﬀerences were
statistically signiﬁcant at all stimulation frequencies (3, 6,
and 9Hz) (Figure 2). The decrease in heart rate remained
stable after i.v. bolus administration of saline solution
(1mL/kg, n = 5). However, these eﬀects caused by electrical
stimulation of the vagus nerve were completely blocked
by prior administration of atropine (0.5mg/kg, n = 10)
(data not shown), conﬁrming the cholinergic nature of the
responses to electrical stimulation.
Low doses of 5-HT (5 and 10μg/kg, n = 10) caused
a signiﬁcant increase in the vagally induced bradycardia
at all stimulation frequencies tested (Figure 2). However,
high doses of 5-HT (100 and 200μg/kg, n = 10) caused
a signiﬁcant decrease in bradycardia at all stimulation
frequencies tested (Figure 2).
3.4. Eﬀects of i.v. Bolus Administration of 5-HT Receptor
Agonists (5-CT, 8-OH-DPAT, CGS-12066B, L-694,247, α-
methyl-5-HT, and 1-phenylbiguanide) on Vagally Induced
Bradycardia in Long-Term Diabetic Rats. In eight-week dia-
betic rats, the bradycardic eﬀects induced by vagal electrical
stimulation were modiﬁed by 5-CT (a selective 5-HT1/7
receptor agonist) depending on the dose administered. At
l o wd o s e s( 5a n d1 0 μg/kg), 5-CT enhanced electrically
induced bradycardia (Figure 3), whereas high doses (50, 100,
and 200μg/kg) inhibited electrically induced bradycardia
(Figure 3).
The enhanced bradycardic eﬀect induced by low doses
of 5-CT was reproduced by administration of the selective
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Figure 1: Change in heart rate response (ΔHR) evoked by
electrical stimulation of the peripheral end of the right vagus in
atenolol (1mg/kg), pretreated (a) normoglycaemic and (b) four-
week diabetic pithed rats before (control; n = 5) and after i.v.
administration of a bolus of 1mL/kg saline solution or 10, 50, 100,
200μg/kg of 5-hydroxytryptamine (5-HT) to normoglycaemic rats
(n = 5) or 10, 50, 100, 200μg/kg of 5-HT to four-week diabetic rats
(n = 5). ∗P<. 05 compared with saline (control).
5-HT1A receptor agonist, 8-OH-DPAT (50μg/kg) (Figure 4).
This eﬀect was signiﬁcant at all stimulation frequencies
tested. However, i.v. bolus administration of the selective
5-HT1B receptor agonist, CGS-12066B (50μg/kg), and the
selective 5-HT1D receptor agonist, L-694,247 (50μg/kg), had
no eﬀect on the bradycardic responses evoked by electricalExperimental Diabetes Research 5
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Figure 2: Changes in heart rate (ΔHR) evoked by electrical stimu-
lation of the peripheral end of the right vagus in atenolol (1mg/kg)
pretreated long-term diabetic pithed rats after i.v. administration of
a bolus of 1mL/kg of saline solution, 5, 10, 50, 100, and 200μg/kg
of 5-HT. ∗P<. 05 compared with saline.
stimulation of the vagus nerve (data not shown). Admin-
istration of the selective 5-HT2 receptor agonist, α-methyl-
5-HT (150μg/kg), or selective 5-HT3 receptor agonist, 1-
phenylbiguanide(150μg/kg),didnotmodifythedecreasesin
heart rate induced by vagal electrical stimulation (Figure 3).
3.5. Eﬀect of i.v. Bolus Administration of 5-HT Receptor
Antagonists (Methiothepin, WAY-100,635, and Pimozide) on
Vagally Induced Bradycardia in Long-Term Diabetic Rats.
In eight-week diabetic pithed rats, administration of either
the selective 5-HT1A receptor antagonist, WAY-100,635
(100μg/kg, n = 5), or the nonselective 5-HT1 receptor
antagonist methiothepin (100μg/kg, n = 5) or the selective
5-HT7 receptor antagonist, pimozide (1mg/kg, n = 5), did
not signiﬁcantly modify the heart rate induced by vagal
electrical stimulation (data not shown).
Pretreatment with methiothepin (100μg/kg) blocked the
potentiatingandinhibitoryeﬀectof5-CTonthebradycardia
induced by vagal stimulation in diabetic rats (Figure 5).
Pretreatment with WAY-100,635 (100μg/kg) reduced the
enhancementofthebradycardiceﬀectcausedbylowdosesof
5-CT (10μg/kg; Figure 3) and abolished the eﬀects of 8-OH-
DPAT (50μg/kg, n = 5; Figure 4).
Administration of the selective 5-HT7 receptor antag-
onist pimozide (1mg/kg) did not modify the potentiating
eﬀect of the lowest 5-CT doses (10μg/kg, n = 5; Figure 6).
However, it abolished the inhibitory action of high doses of
5-CT (100μg/kg, n = 5; Figure 6).
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Figure 3: Changes in heart rate (ΔHR) evoked by electrical
stimulation of the peripheral end of the right vagus in atenolol
(1mg/kg) pretreated diabetic pithed rats after i.v. administration
of a bolus of 1mL/kg of saline solution, 5, 50, and 200μg/kg
of 5-carboxamidotryptamine (5-CT; n = 5f o re a c hd o s e ) ,α-
methyl-5-HT (α-m-5-HT; 150μg/kg), or 1-phenylbiguanide (1-
PBG; 150μg/kg). ∗P<. 05 compared with saline.
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Figure 4: Changes in heart rate (ΔHR) after i.v. administration
of a bolus of 8-hydroxydipropylaminotretalin hydrobromide (8-
OH-DPAT, 50μg/kg; n = 5) and response after i.v. admin-
istration of a bolus of WAY-100,635 (100μg/kg) on the eﬀect
of 8-hydroxydipropylaminotretalin hydrobromide (8-OH-DPAT,
50μg/kg; n = 5) and 5-carboxamidotryptamine (5-CT, 10,
100μg/kg; n = 10) on bradycardia induced by vagal electrical
stimulation in diabetic pithed rats. ∗P<. 05 compared with saline.6 Experimental Diabetes Research
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Figure 5: Changes in heart rate (ΔHR) after i.v. administration
of a bolus of 5-carboxamidotryptamine (5-CT, 10, 100μg/kg)
and response after i.v. administration of a bolus of methiothepin
(100μg/kg) on the enhanced and inhibitory eﬀect of 5-CT (10,
100μg/kg) on bradycardia by vagal electrical stimulation in diabetic
pithed rats. ∗P<. 05 compared with saline.
3.6. Eﬀects of Saline, 5-HT, 5-CT, and 8-OH-DPAT on the
Bradycardia Induced by Exogenous Acetylcholine Administra-
tion in Long-Term Diabetic Rats. Exogenous administration
ofacetylcholine(5and10μg/kg)inlong-termhyperglycemic
ratsproducedasigniﬁcantlyincreasedbradycardiacompared
with normoglycemic rats. However, the bradycardia was less
pronounced than in short-term diabetic rats (Figure 7).
In a groupof rats, bradycardia was induced by exogenous
administration of the muscarinic agonist acetylcholine (1,
5, and 10μg/kg), resulting in dose-dependent decreases in
heart rate. These bradycardic eﬀects, in eight-week diabetic
rats, remained stable after i.v. bolus administration of
saline (1mL/kg, n = 5). However, administration of 5-
HT (10μg/kg, n = 5), 5-CT (10μg/kg, n = 5), or 8-
OH-DPAT (50μg/kg, n = 5) enhanced the bradycardia,
whereas i.v. bolus administration of higher doses of 5-HT
(100μg/kg, n = 5) or 5-CT (100μg/kg, n = 5) inhibited
the bradycardia induced by administration of exogenous
acetylcholine (Figure 8).
4. Discussion
In the present study, we examined the changes induced by
experimental long-term diabetes to 5-HT on the in vivo
cardiac response to activation of parasympathetic nerves.
This was achieved by examining the serotonergic recep-
tors involved in the cholinergic cardiac responses induced
by vagal electrical stimulation or by the administration
of exogenous acetylcholine during experimental alloxan-
induced diabetes.
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Figure 6: Changes in heart rate (ΔHR) after i.v. administration
of a bolus of 5-carboxamidotryptamine (5-CT, 10, 100μg/kg) and
response after i.v. administration of a bolus of pimozide (1mg/kg)
on the enhanced eﬀect and inhibitory eﬀect of 5-CT (10, 100μg/kg)
on bradycardia by vagal electrical stimulation in diabetic pithed
rats. ∗P<. 05 compared with saline.
Alloxan is a diabetogenic agent which induces a syn-
dromeinanimalsresemblingtype1diabetesmellituscharac-
terized by hyperglycemia, hypercholesterolemia, glycosuria,
and raised levels of glycosylated hemoglobin in erythrocytes
[12, 17, 21–24]. This agent, in our experiments, did not
modify heart rate, as previously indicated by Lee et al. [25],
Zola et al. [26], and Howarth et al. [27].
Herein, we showed that there was no signiﬁcant dif-
ference in basal heart rate among the three study groups
(normoglycemic, long-term, and short-term diabetic rats) as
reportedbyusandothers[11,12,28].Thisisincontrastwith
reports that describe a reduced intrinsic heart rate [29]a n d
parasympathetic tonus in diabetes [30].
We showed that, in long-term diabetic rats, the brady-
cardic eﬀect produced by electrical stimulation of the vagus
nerve (at all stimulation frequencies) was lower than the
observed in short-term diabetic rats and was impaired
compared with normoglycemic rats [11, 12]. In 2007, Ago et
al. [31], using diabetic rats, showed an increase in heart rate
induced by vagal stimulation using stimulation frequencies
higher than those used by us (16, 32, and 64Hz).
We also demonstrated that administration of exogenous
acetylcholine (5 and 10μg/kg) in long-term hyperglycaemic
rats produced a more pronounced bradycardia than in
normoglycaemic rats (statistically signiﬁcant diﬀerence).
However, the bradycardia was less pronounced than in
short-term diabetic rats. Our research team and others
have suggested that chemically induced diabetes may elicit
functional defects in cardiac cholinergic nerves [11, 32–
34]. In the heart, inhibitory M2 muscarinic receptors onExperimental Diabetes Research 7
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Figure 7: Changes in heart rate (ΔHR) evoked by exogenous
administration of 1, 5, and 10μg/kg acetylcholine in atenolol
(1mg/kg)pretreatedinnormoglycaemic,four-week,andlong-term
diabetic pithed rats after i.v. administration of a bolus of 1mL/kg.
∗P<. 05 compared with normoglycaemic group.
the nerves limit acetylcholine release [35–37]. The increased
inhibition of acetylcholine release by inhibitory neuronal
M2 muscarinic receptors during experimental diabetes has
been described extensively in diﬀerent experimental models,
including rat lungs [16], the ileum and trachea from diabetic
rats [18], the urinary bladder [38] ,a n de v e ni nh u m a n
cardiac atrium [39]. Therefore, in the present study, we
examined the changes induced by long-term diabetes in the
action that 5-HT exerts on the in vivo cardiac response to
parasympathetic nerves activation.
5-HT is the well-characterized endogenous ligand for all
5-HT receptors. 5-HT had a dual eﬀect on the bradycardia
induced by electrical stimulation in experimental long-
term diabetic rats. This dual eﬀect was reproduced by
the selective 5-HT1/7 receptor agonist 5-CT [40]: at low
doses (5 and 10μg/kg), 5-HT and 5-CT increased the
bradycardia, whereas higher doses (100 and 200μg/kg)
of 5-HT or 5-CT decreased the bradycardic eﬀect at all
stimulation frequencies. In contrast, administration of α-
methyl-5-HT (a selective 5-HT2A/2B/2C receptor agonist) [41]
or 1-phenylbiguanide (a selective 5-HT3 receptor agonist)
[42, 43]h a dn oe ﬀect on vagally induced bradycardia in
diabetic rats. These ﬁndings suggest that, in experimental
long-term (eight-week) diabetes, the serotonergic eﬀects on
bradycardia are mediated through activation of the 5-HT1
receptors but not through activation of the 5-HT2 or 5-
HT3 receptors. We had previously demonstrated that, in
normoglycemic pithed rats, 5-HT2 receptors are involved
in the inhibition of vagally induced bradycardia and that
the 5-HT3 receptor is required for stimulatory action [11].
Therefore, we propose that, in experimental diabetes, as in
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Figure 8: Changes in heart rate (ΔHR) evoked by exogenous
administration of 1, 5, and 10μg/kg acetylcholine in atenolol
(1mg/kg) pretreated in long-term diabetic pithed rats after i.v.
administration of a bolus of 1mL/kg of saline solution, 5-
hydroxytryptamine (5-HT, 10 and 100μg/kg; n = 10), 5-
carboxamidotryptamine (5-CT 10 and 100μg/kg; n = 10),
or 8-hydroxydipropylaminotretalin hydrobromide (8-OH-DPAT
50μg/kg; n = 5). ∗P<. 05 compared with saline.
normoglycaemia [11, 12], the serotonergic system interferes
with cholinergic cardiac transmission, producing enhance-
ment and inhibition of the bradycardic eﬀect induced by
vagal stimulation.
Several authors have hypothesized that, at gastrointesti-
nal level, in normoglycaemic animals, 5-HT1 receptors are
involved in the reduction of acetylcholine release [10, 44].
To determine which 5-HT1 receptor subtype is responsible
for the action observed in this paper, we used antagonists
and selective 5-HT1 agonists in our experimental model of
diabetes.
In long-term diabetic rats, we noted that the increases
observed in the vagally induced bradycardia after admin-
istration of low doses of 5-HT and 5-CT (selective 5-
HT1/7 receptor agonist) were mimicked, at all stimulation
frequencies, by the selective 5-HT1A receptor agonist 8-OH-
DPAT [45].
However, and unlike the eﬀects observed in four-week
diabetic rats, L-694,247, a selective agonist for nonrodent
5-HT1B and 5-HT1D receptors [46], failed to mimic the
inhibitory action on vagally induced bradycardia elicited by
high doses of 5-CT. Also, CGS-12066B, a rodent 5-HT1B
receptor agonist [47], had no eﬀect on vagally induced
bradycardia. These ﬁndings suggest that the 5-HT1A receptor
subtype is involved in regulating the stimulatory eﬀect
observed.
Regarding the antagonists utilized, the selective 5-HT1A
antagonist WAY-100,635 [48] and the selective 5-HT7 recep-
tor antagonist pimozide [49] did not aﬀect the vagally8 Experimental Diabetes Research
induced bradycardia in long-term diabetic rats. However,
the vagally induced bradycardia was slightly enhanced by
methiothepin(nonselective5-HT1 receptorantagonist)[50].
These ﬁndings are consistent with reports describing an
intrinsic eﬀect on acetylcholine release in rat striatal slices
for methiothepin [51].
We have previously indicated a dual eﬀect for 5-CT in
four-week diabetic rats [12]. This eﬀect was reproduced in
eight-week diabetic rats, but the receptor subtype involved
in the inhibitory eﬀect was diﬀerent. Furthermore, in the
present study we showed that, in long-term diabetic rats (8
weeks), (i) methiothepin [40], a nonselective 5-HT receptor
antagonist, blocked the enhanced and inhibitory eﬀects
of 5-CT on the vagally induced bradycardia; (ii) 8-OH-
DPAT (selective 5-HT1A receptor agonist) could enhance the
bradycardia produced by vagal stimulation; (iii) the action
of 8-OH-DPAT was abrogated by WAY-100,635 (selective
5-HT1A antagonist) [52]; (iv) pimozide (selective 5-HT7
antagonist) [49] blocked the inhibitory eﬀect of high doses
of 5-CT; (v) after pretreatment with pimozide, 5-CT could
increase the bradycardia produced by vagal stimulation at all
doses tested.
Diabetes mellitus is associated with severe debilitating
complications that include diabetic autonomic neuropathy
characterized in part by impaired cardiac parasympathetic
responsiveness [13]. Parasympathetic dysfunction in the
diabetic heart may lead to an autonomic imbalance which
may predispose the heart to ventricular arrhythmias and
sudden death. Our ﬁndings suggest a possible peripheral
action of serotonergic receptors in modulating cholinergic
transmission, in addition to the well-known central 5-HT1A
receptor regulation in cardiovascular eﬀects [7, 53]. Also,
the role of 5-HT7 receptors in facilitating vagal outﬂow
activation to the heart [1, 8, 54]h a sb e e ns u g g e s t e d .
We also showed that the dual eﬀect (stimulatory and
inhibitoryactions)ofthevagallyinducedbradycardiacaused
by5-HTand5-CTpersistedifthebradycardiawaselicitedby
exogenous acetylcholine in long-term diabetic rats.
These results conﬁrm the pre- and postjunctional nature
of these serotonergic actions in long-term diabetes. Never-
theless, these ﬁndings are in contrast with results described
by our research team in normoglycaemic rats [11]a n dw e r e
similar to those found in four-week diabetic pithed rats [12],
The present study showed that long-term diabetes
changed the responses to 5-HT on the in vivo cardiac
response to activation of parasympathetic nerves. Peripheral
5-HT1A and5-HT7 receptorsmayhaveaphysiologicalrolein
the regulation of cardiovascular reﬂexes, controlling changes
in parasympathetic (vagal) drive to the heart. In this line,
in the nucleus tractus solitaries, Oskutyte et al. [55]h a v e
reported the presence of 5-HT1A and 5-HT7 receptors, which
play an important role in cardiovascular reﬂex activation of
parasympathetic outﬂow to the heart.
In conclusion, experimental long-term diabetes induces
changesinthenatureandthetype/subtypeof5-HTreceptors
involved in vagal bradycardia induced by electrical stimu-
lation. Activation of the 5-HT1A receptor subtype induces
enhancement of vagally induced bradycardia, whereas atten-
uation of this bradycardia is due to activation of the 5-HT7
receptor subtype. The eﬀects induced by 5-HT occur at the
pre- and postjunctional level in long-term diabetic pithed
rats. Based on these and our previous results, the alloxan-
induced diabetes in rats (short- and long-term diabetes)
is an appropriate model to study the role of 5-HT and
its receptors in the development and progression of the
autonomic and endothelial dysfunction due to diabetes
mellitus type 1. Further investigation is warranted to deter-
mine whether 5-HT7 receptors play a pathophysiological
role in the autonomic dysfunction due to this chronic
disease.
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